A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer

A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer

Abstract The objective of this multicenter, single‐arm trial (ChiCTR1900022293) was to explore the efficacy and safety of neoadjuvant therapy with epirubicin, cyclophosphamide, and pyrotinib followed by docetaxel, trastuzumab, and pyrotinib (ECPy‐THPy) in the treatment of patients with stage II–III...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Qiyun Shi, Xiaowei Qi, Peng Tang, Linjun Fan, Li Chen, Shushu Wang, Yan Liang, Ying Hu, Minghao Wang, Lin Ren, Guozhi Zhang, Xuanni Tan, Long Yuan, Junze Du, Xiujuan Wu, Mengyuan Wang, Hongying Che, Pengwei Lv, Dejie Chen, Jinhui Hu, Qiuyun Li, Yanwu Zhang, Kunxian Yang, Yuan Zhong, Chuang Chen, Zemin Zhou, Liyuan Qian, Jingwei Zhang, Mingde Ma, Yi Sun, Yi Zhang, Jun Jiang
Materialtyp: Artikel
Språk:English
Publicerad: Wiley 2023-12-01
Serie:MedComm
Ämnen:
HER2‐positive breast cancer
multicenter study
neoadjuvant therapy
pyrotinib
trastuzumab
Länkar:https://doi.org/10.1002/mco2.435

Internet

https://doi.org/10.1002/mco2.435

Liknande verk